Skip to main content

Table 2 Estimates of cardiovascular risk according to the number of ideal cardiovascular health metrics in the RIVANA cohort (n = 3826)

From: Association of ideal cardiovascular health with cardiovascular events and risk advancement periods in a Mediterranean population-based cohort

Endpoint

Number of metrics for ideal cardiovascular health, HR (95% CI)

P-trend1

0–2 (n = 767)

3 (n = 1062)

4 (n = 948)

5–7 (n = 1049)

Major cardiovascular diseasea

 Events/person-years

53/9126

83/12594

46/11482

12/13156

 

 Incidence rate/10,000 person years

58.07

65.90

40.06

9.12

 

 Unadjusted model

1.00 (ref.)

1.14 (0.81–1.61)

0.69 (0.46–1.02)

0.16 (0.08–0.29)

< 0.001

 Sex- and age-adjusted model

1.00 (ref.)

1.12 (0.79–1.58)

0.78 (0.52–1.16)

0.31 (0.16–0.58)

< 0.001

 MV-adjusted modelb

1.00 (ref.)

1.12 (0.79–1.59)

0.79 (0.53–1.18)

0.32 (0.17–0.60)

< 0.001

Rate advancement periods (years)

  MV-adjusted modelb

0.00 (ref.)

1.44 (− 2.92, 5.80)

− 2.94 (− 7.94, 2.06)

− 14.36 (− 22.85, − 5.87)

 

Myocardial infarction

 Events/person-years

20/9213

31/12739

11/11579

5/13175

 

 Incidence rate/10,000 person years

21.71

24.33

9.50

3.80

 

 Unadjusted model

1.00 (ref.)

1.12 (0.64–1.97)

0.44 (0.21–0.91)

0.18 (0.07–0.47)

<  0.001

 Sex- and age-adjusted model

1.00 (ref.)

1.18 (0.67–2.08)

0.52 (0.25–1.09)

0.31 (0.11–0.84)

0.004

 MV-adjusted modelb

1.00 (ref.)

1.18 (0.67–2.08)

0.53 (0.25–1.10)

0.32 (0.12–0.87)

0.006

Rate advancement periods (years)

  MV-adjusted modelb

0.00 (ref.)

3.74 (− 9.24, 16.73)

− 14.49 (− 32.66, 3.67)

− 27.79 (− 54.93, − 1.34)

 

Stroke

 Events/person-years

23/9216

39/12751

20/11545

5/13184

 

 Incidence rate/10,000 person years

24.96.

30.59

17.32

37.92

 

 Unadjusted model

1.00 (ref.)

1.23 (0.73–2.06)

0.69 (0.38–1.26)

0.15 (0.06–0.40)

< 0.001

 Sex- and age-adjusted model

1.00 (ref.)

1.17 (0.69–1.96)

0.77 (0.42–1.40)

0.30 (0.11–0.80)

0.011

 MV-adjusted modelb

1.00 (ref.)

1.15 (0.69–1.94)

0.76 (0.41–1.39)

0.29 (0.11–0.77)

0.009

Rate advancement periods (years)

  MV-adjusted modelb

0.00 (ref.)

1.47 (− 3.92, 6.86)

− 2.87 (− 9.13, 3.39)

− 12.77 (− 23.44, − 2.10)

 

Death from cardiovascular causes

 Events/person-years

17/9313

27/12907

20/11642

2/13204

 

 Incidence rate/10,000 person years

18.26

20.92

17.18

1.51

 

 Unadjusted model

1.00 (ref.)

1.15 (0.63–2.11)

0.94 (0.49–1.79)

0.08 (0.02–0.36)

< 0.001

 Sex- and age-adjusted model

1.00 (ref.)

1.03 (0.56–1.90)

1.02 (0.53–1.95)

0.18 (0.04–0.77)

0.059

 MV-adjusted modelb

1.00 (ref.)

1.04 (0.57–1.92)

1.03 (0.54–1.97)

0.19 (0.04–0.80)

0.072

Rate advancement periods (years)

  MV-adjusted modelb

0.00 (ref.)

0.34 (− 4.63, 5.31)

0.25 (− 5.05, 5.55)

− 13.77 (− 26.23, − 1.,31)

 

Expanded composite major cardiovascular diseasec

 Events/person-years

94/8868

112/12409

64/11372

22/13084

 

 Incidence rate/10,000 person years

106.00

90.25

56.28

16.81

 

 Unadjusted model

1.00 (ref.)

0.85 (0.65–1.12)

0.53 (0.39–0.73)

0.16 (0.10–0.25)

< 0.001

 Sex- and age-adjusted model

1.00 (ref.)

0.85 (0.64–1.12)

0.61 (0.44–0.84)

0.30 (0.19–0.49)

< 0.001

 MV-adjusted modelb

1.00 (ref.)

0.85 (0.65–1.12)

0.61 (0.44–0.84)

0.31 (0.19–0.49)

< 0.001

Rate advancement periods (years)

  MV-adjusted modelb

0.00 (ref.)

− 2.33 (− 6.36, 1.69)

− 7.16 (− 11.94, − 2.37)

− 17.22 (− 24.84, − 9.59)

 
  1. Bold values are statistically significant at P < 0.05
  2. Abbreviations: CI confidence interval, HR hazard ratio, M-V multivariate, Ref. reference
  3. 1P-value for linear trend
  4. aMajor cardiovascular disease was defined as occurrence of myocardial infarction, stroke, or cardiovascular death
  5. bMultivariate model adjusted for age (continuous), sex, higher level of attained education (primary or less, secondary, and college/university), and occupation (executives/managers, clerical workers, and manual workers)
  6. cExpanded composite major cardiovascular disease included myocardial infarction, stroke, cardiovascular death, other ischemic heart diseases, other cerebrovascular diseases, and peripheral arterial disease (Supplemental Fig. S1)